{"id":"C2004L04923","name":"Health Insurance (1992-1993 Pathology Services Table) Regulations","slug":"health-insurance-1992-1993-pathology-services-table-regulations","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":"336 of 1992","makingDate":null,"administeringDepartment":null,"currentVersion":{"id":27727,"registerId":"commonwealth-C2004L04923-current","compilationNumber":null,"startDate":"2026-04-01","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Health Insurance (1992-1993 Pathology Services Table) Regulations","content":"![](image.001.png)\n\nStatutory Rules 1992 No. 3361\n\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\nHealth Insurance (1992-1993 Pathology Services Table) Regulations\n\nI, The Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, make the following Regulations under the Health Insurance Act 1973.\n\nDated 20 October 1992.\n\nBILL HAYDEN\n\nGovernor-General\n\nBy His Excellency’s Command,\n\nB. HOWE\n\nMinister of State for Health, Housing\n\nand Community Services\n\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\nCitation\n\n1. These Regulations may be cited as the Health Insurance (1992-1993 Pathology Services Table) Regulations.\n\nCommencement\n\n2. These Regulations commence on 1 November 1992.\n\nRepeal\n\n3. Statutory Rules 1991 No. 442, and 1992 Nos. 23, 46 and 273 are repealed.\n\nPathology services table\n\n4. The table of pathology services in the Schedule is prescribed for the purposes of subsection 4a (2) of the Health Insurance Act 1973.\n\nSCHEDULE\n\nTABLE OF PATHOLOGY SERVICES\n\nRULES OF INTERPRETATION\n\n1. (1) In this table, unless the contrary intention appears:\n\n“patient episode” means:\n\n(a) a pathology service to which rule 3a refers that is provided in the circumstances described in that rule that relate to the service; and\n\n(b) except in the case of a pathology service to which paragraph (a) refers—a pathology service or pathology services, whether specified in a single item or in more than 1 items, provided for a single patient whose need for the service or services was determined under subsection 16a (1) of the Act on the same day, whether rendered by an approved pathology practitioner or more than 1 approved pathology practitioner on the same day or on different days;\n\n“recognised pathologist” means a medical practitioner recognised as a specialist in pathology under a determination under subsection 61 (3) of the Act;\n\n“the Act” means the Health Insurance Act 1973.\n\n(2) In these Rules, a reference to a request to an approved pathology practitioner includes a reference to a request for a pathologist-determinable service to which subsection 16a (6) of the Act applies.\n\n \nSCHEDULE—continued\n\n(3) Unless the contrary intention appears, a reference in this table by number to an item that is not included in this table is a reference to the correspondingly numbered item in the general medical services table or the diagnostic imaging services table, as each case requires.\n\n2. (1) If a service is described:\n\n(a) in an item in general terms; and\n\n(b) in another item in specific terms:\n\nonly the item that describes the service in specific terms applies to the service.\n\n(2) If:\n\n(a) a service is described in 2 or more items; and\n\n(b) subrule (1) does not apply;\n\nonly the item that provides the lower or lowest fee for the service applies to the service.\n\n3. (1) In subrule (2), “service” includes an assay, estimation and test.\n\n(2) Subject to rule 3a, 2 or more pathology services rendered for a patient following 2 or more requests are taken to have been rendered following a single request if:\n\n(a) the services are listed in the same item; and\n\n(b) the patient’s need for the services was determined under subsection 16a (1) of the Act on the same day even if they are rendered by an approved pathology practitioner on more than one day.\n\n3a. (1) Rule 3 does not apply to:\n\n(a) a pathology service specified in item 66201, other than an estimation of cholesterol, fructosamine, lithium or triglycerides; or\n\n(b) the quantitative estimation of 1 or more fractions of neonatal bilirubin specified in item 66273;\n\nif:\n\n \nSCHEDULE—continued\n\n(c) the service is rendered in relation to a single specimen taken on each of not more than 4 occasions in a period of 24 hours; and\n\n(d) the service is rendered to a patient in a hospital unit where:\n\n(i) the presence of 1 nurse is required for each group of not more than 4 patients; and\n\n(ii) the condition of the patients is continuously observed in relevant respects; and\n\n(e) in order to render the service, an approved pathology practitioner who is a recognised pathologist has to arrange for a member of the laboratory staff of the approved pathology authority concerned to undertake duties in respect of the service that are in addition to the usual duties of the staff member.\n\n(2) Rule 3 does not apply to any of the following pathology services rendered in relation to a single specimen taken on each of not more than 6 occasions in a period of 6 months:\n\n(a) estimation of prothrombin time in respect of a patient undergoing anticoagulant therapy;\n\n(b) quantitative estimation of lithium in respect of a patient undergoing lithium therapy;\n\n(c) a service specified in item 65007 in relation to a patient undergoing chemotherapy for neoplastic disease or immunosuppressant therapy;\n\n(d) a service specified in item 65007 in relation to methotrexate, gold or penicillamine therapy of a patient;\n\n(e) a service specified in item 66201 in relation to methotrexate therapy of a patient;\n\n(f) quantitative estimation of urea, creatinine and electrolytes in relation to:\n\n(i) cis-platinum therapy of a patient; or\n\n(ii) chronic renal failure of a patient being treated in a dialysis program conducted by a recognised hospital.\n\n(3) This rule does not apply in relation to a pathology service unless the account for fees in respect of the service is endorsed with the words “Rule 3 Exemption”.\n\nSCHEDULE—continued\n\n4. If:\n\n(a) a pathology service to which an item of the table applies is rendered for a patient in accordance with a request; and\n\n(b) another pathology service is rendered for the patient in accordance with the request; and\n\n(c) an item of the table:\n\n(i) applies to the other service; and\n\n(ii) is referred to in the item mentioned in paragraph (a);\n\nthe other service is treated as if it were part of the service referred to in paragraph (a).\n\nExample:\n\nDr Proctor requests an extended blood grouping test (covered by item 65019) and the test includes a basic blood grouping test (covered by item 65017). Item 65017 is referred to in item 65019. Benefit is payable under item 65019 for the extended blood grouping test but benefit is not payable separately under item 65017 for the basic blood grouping test.\n\n5. For the purposes of items 65001 to 66200 (inclusive):\n\n(a) if pathology services of a kind referred to in item 65017 or 65019 are rendered for a patient during a period when the patient is in hospital, the item applies only to the first pathology service of that kind rendered for the patient during that period; and\n\n(b) tests (except the tests mentioned in item 65023) carried out on material stored from a previous patient episode in response to a later request are treated as part of that previous patient episode if the second request is made within 14 days of that previous patient episode.\n\n5a. (1) In this rule:\n\n“designated pathology service” means a pathology service specified in item 66241, 66313 or 69241.\n\n \nSCHEDULE—continued\n\n(2) Subject to subrule (3), if an approved pathology practitioner in an approved pathology authority:\n\n(a) has been requested to render a pathology service that specified 2 or more estimations comprised in a designated pathology service; and\n\n(b) is unable to perform 1 or more, but not all, of the estimations because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority in relation to that estimation or those estimations; and\n\n(c) requests an approved pathology practitioner in another approved pathology authority to render 1 or more, but not all, of the estimations;\n\nthe service rendered by the second-mentioned practitioner is taken to be the designated pathology service.\n\n(3) Items 73901 to 73917 (inclusive) do not apply to the second-mentioned approved pathology practitioner in subrule (2).\n\n6. For the purposes of items 66201 to 69200 (inclusive):\n\n(a) if a pathology service involving the measurement of a substance in urine requires a 24 hour urine collection, or calculation of a substance/creatinine ratio, the service is treated as including any estimation of creatinine in other fluids necessary for the calculation; and\n\n(b) tests carried out on material stored from a previous patient episode in response to a later request are treated as part of that previous patient episode if the second request is made within 14 days of that previous patient episode.\n\n7. For the purposes of items 69201 to 71000 (Inclusive):\n\n(a) “serial examinations or cultures” means examinations or cultures requested on 1 occasion whether or not;\n\n(i) the materials are received on different days by the approved pathology practitioner; or\n\n(ii) the examinations or cultures were requested on 1 or more request forms by the treating practitioner; and\n\n \nSCHEDULE—continued\n\n(b) tests carried out on material stored from a previous patient episode in response to a later request are treated as part of that previous patient episode if the second request occurs within 14 days of that previous patient episode.\n\n8. For the purposes of items 71001 to 72800 (inclusive):\n\n(a) in items 71025, 71027, 71029 and 71031, the estimation of a single antibody includes qualitative and quantitative assays for that antibody; and\n\n(b) tests carried out on material stored from a previous patient episode in response to a later request are treated as part of that previous patient episode if the second request occurs within 14 days of that previous patient episode.\n\n9. For the purposes of items 72801 to 73040 (inclusive):\n\n(a) “biopsy material” means all tissue received by the approved pathology practitioner from an operation, or a group of operations, performed on a patient at the same time, other than a bone marrow biopsy; and\n\n(b) if:\n\n(i) a pathology service that is the examination of biopsy material is rendered under any of those items; and\n\n(ii) a further pathology service mentioned in any of those items is also rendered using that biopsy material;\n\nthose pathology services are treated as 1 pathology service.\n\n10. for the purposes of items 73041 to 73280 (inclusive), “serial examinations” means examinations requested on 1 occasion whether or not:\n\n(a) the materials are received on different days by the approved pathology practitioner; or\n\n(b) the examinations were requested on 1 or more request forms by the treating practitioner.\n\n \nSCHEDULE—continued\n\n11. (1) For the purposes of this rule and items 73901 to 73921 (inclusive):\n\n“approved pathology authority” has the same meaning as in Division 4a of Part IIa of the Act;\n\n“institution” means a place (other than a hospital, a nursing home or accommodation for aged persons that is attached to a nursing home or situated within a nursing home complex) at which residential accommodation or day care is, or both residential accommodation and day care are, made available to:\n\n(a) disadvantaged children; or\n\n(b) juvenile offenders; or\n\n(c) aged persons; or\n\n(d) chronically ill psychiatric patients; or\n\n(e) homeless persons; or\n\n(f) unemployed persons; or\n\n(g) persons suffering from alcoholism; or\n\n(h) persons addicted to drugs; or\n\n(i) physically or mentally handicapped persons.\n\n“licensed collection centre” has the same meaning as in Part IIa of the Act;\n\n“prescribed laboratory” means a laboratory operated by:\n\n(a) the Commonwealth; or\n\n(b) a State; or\n\n(c) an authority of a State or Territory; or\n\n(d) the Northern Territory; or\n\n(e) the Australian Capital Territory; or\n\n(f) an Australian tertiary education institution.\n\n“specimen collection centre” has the same meaning as in Part IIA of the Act;\n\n“temporary collection centre” has the same meaning as in Part IIA of the Act;\n\n“treating practitioner” has the same meaning as in paragraph 16A (1)(a) of the Act.\n\n \nSCHEDULE—continued\n\n(2) A service mentioned in items 73901 to 73921 (inclusive) applies to a pathology service when rendered by, or on behalf of, an approved pathology practitioner who is a recognised pathologist unless:\n\n(a) the service is rendered upon a request made in the course of an out-patient service at a recognised hospital; or\n\n(b) the service is rendered upon a request made for a patient who is a private patient in a recognised hospital when the request was made; or\n\n(c) the pathology equipment of a recognised hospital, or prescribed laboratory, is used rendering the service; or\n\n(d) a member of the staff of a recognised hospital, or prescribed laboratory, participates in the service in the course of the member’s employment with the hospital or laboratory.\n\n(3) A service mentioned in items 73901 to 73921 (inclusive) does not apply to a pathology service:\n\n(a) to which subsection 16a (7) of the Act applies; or\n\n(b) unless at least one of items 65001 to 73529 (inclusive) also applies to that service.\n\n(4) If one item of items 73901 to 73917 (inclusive) applies to a patient episode, none of the remainder of those items applies to that patient episode.\n\n(5) Item 73921:\n\n(a) applies only to the approved pathology practitioner or approved pathology authority to whom the specimen mentioned in the item was referred; and\n\n11a. If item 73921 applies to a patient episode, none of items 73901 to 73917 (inclusive) applies to any pathology service rendered by the approved pathology authority or the approved pathology provider in respect of that patient episode.\n\n12. The abbreviations at the end of the table may be used to identify particular pathology services or groups of pathology services.\n\n \nSCHEDULE—continued\n\nSERVICES AND FEES\n\nGROUP P1—HAEMATOLOGY\n\n| 65001 | Blood count consisting of erythrocyte count, C-reactive protein, erythrocyte sedimentation rate, blood viscosity, haematocrit, haemoglobin, platelet count, leucocyte count, reticulocyte count—1 or 2 procedures | $5.60 |\n| ----- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------ |\n| | | |\n| 65003 | 3 or more procedures to which item 65001 applies, including any calculation or measurement of erythrocyte or other indices | $7.60 |\n| | | |\n| 65005 | Examination of blood film, with or without 5 part differential cell count, or 5 part differential cell count with or without examination of blood film, and if performed, any of these additional services—Direct Coombs test, tests for heterophile antibodies, cold agglutinins, examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron, or examination of a blood film with alpha-naphthyl acetate esterase, choloroacetate esterase, neutrophil alkaline phosphatase, nitroblue tetrazolium, periodic acid Schiff, Sudan Black stains, or Kleihauer test for HbF on blood film, including any services specified in item 65027 | $10.00 |\n| | | |\n| 65007 | Full blood examination consisting of items 65003 and 65005 | $17.30 |\n| | | |\n| 65009 | Erythrocytes, qualitative or quantitative assessment of haemolysis or metabolic enzymes by—erythrocyte autohaemolysis test, erythrocyte fragility test, sugar water test, erythrocyte metabolic enzyme test, heat denaturation test, isopropanol precipitation test, acid haemolysis test, and quantitation of muramidase in serum or urine - 1 or more procedures | $23.00 |\n| | | |\n| 65011 | Tests for the diagnosis of haemoglobinopathy consisting of haemoglobin electrophoresis and 2 of the following—examination for HbH, quantitation of HbA2 or HbF, including any services specified in items 65001, 65003, 65005 and 65007 | $36.00 |\n| | | |\n\n \nSCHEDULE—continued\n\n| 65013 | Histopathological examination of sections of bone marrow trephine biopsy including where indicated, examination of marrow smears and any special stains and immunochemical techniques, including any services specified in items 65001, 65003, 65005, 65007 and 65015 | $110.00 |\n| ----- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------- |\n| | | |\n| 65015 | Bone marrow examination of aspirated material including any special stains, immunochemical techniques and clot sections where necessary, including any services specified in items 65001, 65003, 65005 and 65007 | $80.00 |\n| | | |\n| 65017 | Blood grouping, including back-grouping when performed—ABO and Rh (D antigen) | $9.70 |\n| | | |\n| 65019 | Blood grouping—Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system—1 or more systems, including any services specified in item 65017 | $19.20 |\n| | | |\n| 65021 | Blood grouping, including back-grouping when performed, and examination of serum for Rh and other blood group antibodies, including identification and quantitative estimation of any antibodies detected, and including any services specified in items 65001, 65003, 65005 and 65007 | $36.00 |\n| | | |\n| 65023 | Compatibility testing, including all necessary grouping checks of patient and donor, examination for antibodies, identification and, if necessary, quantitative estimation of any antibodies detected and any services specified in items 65001, 65003, 65005, 65007, 65017 and 65021 including all testing performed on any 1 day | $88.00 |\n| | | |\n| 65025 | Examination of serum for blood group antibodies including identification and, if necessary, quantitative estimation of any antibodies detected | $15.80 |\n| | | |\n| 65027 | Direct Coombs test, qualitative or quantitative test for cold agglutinins, or heterophile antibodies, qualitative spectroscopic examination of blood for abnormal haemoglobins, qualitative test for red cell porphyrins and detection of metalbumin (Schumm’s test) including those services specified in items 65005 and 65007 - 1 or more tests | $8.80 |\n| | | |\n\nSCHEDULE—continued\n\n| 65029 | Skin bleeding time, coagulation time, prothrombin time, activated partial thromboplastin time, thrombin time (including test for presence of an inhibitor and serial tests for fibrinolysis), test for factor XIII deficiency, fibrinogen, or 1 of—fibrinogen degradation products, fibrin monomer or D-dimer—1 estimation | $12.10 |\n| ----- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------ |\n| | | |\n| 65031 | 2 estimations specified in item 65029 | $16.00 |\n| | | |\n| 65033 | 3 estimations specified in item 65029 | $19.90 |\n| | | |\n| 65035 | 4 or more estimations specified in item 65029 | $23.80 |\n| | | |\n| 65037 | Quantitative assay, by 1 or more techniques, of plasminogen, antithrombin III, Protein C, Protein S, heparin cofactor II, euglobulin clot lysis time and test for lupus anticoagulant—1 estimation | $24.00 |\n| | | |\n| 65039 | 4 or more estimations specified in item 65037 | $76.00 |\n| | | |\n| 65041 | Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or similar substance—1 or more estimations | $47.50 |\n| | | |\n| 65043 | Heparin assay, only when monitoring a patient on subcutaneous heparin or low molecular weight heparin —1 or more estimations | $31.50 |\n| | | |\n| 65045 | Quantitative assay of Von Willebrand’s factor antigen (factor VIII related antigen), Von Willebrand’s factor (ristocetin cofactor), factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, Passovy factor —1 estimation | $31.70 |\n| | | |\n| 65047 | 2 estimations as specified in item 65045 | $45.70 |\n| | | |\n| 65049 | 3 or more estimations as specified in item 65045 | $59.70 |\n| | | |\n| | | |\n\n \nSCHEDULE—continued\n\n| | GROUP P2—CHEMICAL | |\n| ----- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------ |\n| | | |\n| 66201 | Quantitative estimation in serum, plasma, urine or any other body fluid, by any method except by reagent strip with or without reflectance meter or electrophoresis of—alanine aminotransferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total and any fractions), calcium (total, dialysed or ionized), chloride, cholesterol, creatine kinase, creatine kinase isoenzymes (when not performed as specified in item 66245), creatinine, fructosamine, gamma glutamyl transpeptidase, globulin, glucose, lactate dehydrogenase, lipase, lithium, magnesium, phosphate, potassium, total protein, sodium, triglycerides, urate, urea - 1 estimation | $9.80 |\n| | | |\n| 66203 | 2 estimations specified in item 66201 | $11.85 |\n| | | |\n| 66205 | 3 estimations specified in item 66201 | $13.90 |\n| | | |\n| 66207 | 4 estimations specified in item 66201 | $15.95 |\n| | | |\n| 66209 | 5 estimations specified in item 66201 | $18.00 |\n| | | |\n| 66211 | 6 or more estimations specified in item 66201 | $20.10 |\n| | | |\n| 66213 | Qualitative estimation by any method, except by reagent strip or dip-stick of the following urine constituents—bilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen or pH measurement of body fluids other than urine (excepting urine acidification test), or cryoglobulins or cryofibrinogen in plasma - 1 or more estimations | $9.50 |\n| | | |\n| 66215 | Quantitative estimation of cryoglobulins or cryofibrinogen after a positive result for cryoglobulin is obtained in any service specified in item 66213 (including provision of that service)—1 or more estimations | $14.40 |\n| | | |\n| 66217 | Qualitative estimation by any method except by reagent strip or dip-stick of the following faecal constituents—haemoglobin, porphyrins, reducing substances—each estimation, to a maximum of 3 estimations, taken on separate days | $6.30 |\n\nSCHEDULE—continued\n\n| | | |\n| ----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------ |\n| 66219 | Immunological detection of human haemoglobin in faeces, including any additional services specified in item 66217—1 estimation in any 28 day period | $12.00 |\n| | | |\n| 66223 | Osmolality, estimation by osmometer, in serum or in urine—1 or more estimations | $24.00 |\n| | | |\n| 66225 | Quantitative estimation of blood gases including tests performed from—pO2, oxygen saturation, pCO2, bicarbonate, pH, and any other measurement (eg. haemoglobin, potassium) or calculation performed on the same specimen—1 or more estimations on 1 specimen | $32.50 |\n| | | |\n| 66227 | Estimation of blood gases as specified in item 66225 on each specimen in excess of 1 to a maximum of 6 specimens within any 1 day | $8.60 |\n| | | |\n| 66229 | Calculus, analysis of 1 or more | $29.50 |\n| | | |\n| 66231 | Drug or chemical assays—including all qualitative and quantitative tests on blood, urine or other body fluid for a drug or drugs of abuse, including illegal drugs and legally available drugs taken other than in appropriate dosage, ingested or absorbed toxic chemicals including any services specified in items 66235, 66237 and 66239, but excluding the surveillance of sports people and athletes for performance improving substances—1 or more assays | $40.00 |\n| | | |\n| 66233 | Drug assays—including all qualitative and quantitative estimations on blood, urine or other body fluid for a drug or drugs of abuse or a therapeutic drug on a sample collected from a patient participating in a drug abuse treatment programme, or being treated for drug effects or under a court order or parole board supervision, but excluding the detection of nicotine and metabolites in smoking withdrawal programmes—each assay to a maximum of 4 assays within any 28 day period | $20.00 |\n| | | |\n| 66235 | Drug assay —quantitative estimation on blood or other body fluid by any method or methods of a drug being used therapeutically for the patient from whom the specimen was taken and not elsewhere specified in the Schedule—1 estimation | $20.00 |\n| | | |\n\nSCHEDULE—continued\n\n| 66237 | 2 estimations specified in item 66235 | $28.00 |\n| ----- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------ |\n| | | |\n| 66239 | 3 or more estimations specified in item 66235 | $36.00 |\n| | | |\n| 66241 | Estimations specified in any of items 66235 to 66239 (inclusive), if the number of estimations relating to the same patient episode does not exceed 3—each estimation to a maximum of 2 estimations | $8.00 |\n| | | |\n| 66243 | Amniotic fluid, spectrophotometric examination of, estimation of lecithin/sphingomyelin ratio, palmitic acid, phosphatidylglycerol or lamellar body phospholipid—1 or more examinations or estimations | $31.50 |\n| | | |\n| 66245 | Electrophoresis, quantitative or qualitative of serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, or the isoenzymes of lactate dehydrogenase, alkaline phosphatase and creatine kinase or lipoprotein electrophoresis (only when the cholesterol is >6.5mmol/l and triglyceride >3.0 mmol/l or in the diagnosis of types III and IV hyperlipidaemia), including the preliminary quantitation of total protein, albumin and globulin or of total relevant enzyme activity—1 examination to a maximum of 2 examinations in any 12 month period | $29.50 |\n| | | |\n| 66247 | Electrophoresis, quantitative or qualitative of concurrently collected, or collected within a 28 day period, serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, including the preliminary quantitation of total protein, albumin and globulin, or of total relevant enzyme activity—2 or more examinations | $44.00 |\n| | | |\n| 66255 | Alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-2-macroglobulin, quantitative estimation in serum, urine or other body fluid—1 or more estimations | $19.40 |\n| | | |\n| 66257 | C-1 esterase inhibitor, quantitative estimation | $19.40 |\n| | | |\n| 66258 | C-1 esterase inhibitor, functional assay | $43.50 |\n| | | |\n\n \nSCHEDULE—continued\n\n| 66259 | Alpha-fetoprotein, beta-2-microglobulin, caeruloplasmin, ferritin (except when part of item 66263), haptoglobulins, microalbumin in proven diabetes mellitus, prealbumin, prostate specific antigen, prostatic acid phosphatase, transferrin (except when part of item 66263) - quantitative estimation in serum, urine or other body fluid—1 estimation | $19.40 |\n| ----- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------ |\n| | | |\n| 66260 | 2 or more estimations as specified in item 66259 | $36.00 |\n| | | |\n| 66261 | CA-125 antigen, CA-15.3 antigen, CA-19.9 antigen, carcinoembryonic antigen (CEA), mammary serum antigen, mucin-like carcinoma associated antigen (1 or more fractions), neuron-specific enolase, thyroglobulin in serum or other body fluid, in the monitoring or confirmation of malignancy, quantitative estimation—1 estimation | $19.40 |\n| | | |\n| 66262 | 2 or more estimations specified in item 66261 | $36.00 |\n| | | |\n| 66263 | Iron studies consisting of quantitative analysis of iron, transferrin or iron binding capacity and ferritin | $38.00 |\n| | | |\n| 66265 | Serum B12, serum folate—1 or more estimations within any 28 day period | $24.00 |\n| | | |\n| 66267 | Red cell folate and serum B12 and, if required, serum folate, to a maximum of 3 estimations in any 12 month period | $43.50 |\n| | | |\n| 66269 | Vitamins, quantitative estimation in blood, urine or other body fluid, by direct or indirect means, of vitamins A, B1, B2, B3, B6, C, and E —1 or more estimations within any 6 month period | $29.50 |\n| | | |\n| 66271 | Vitamin D or D fractions - 1 or more estimations | $29.50 |\n| | | |\n| 66273 | Acetoacetate, alcohol, amino acids, ammonia, angiotensin converting enzyme, betahydroxybutyrate, cholinesterase, cystine (cysteine), total free fatty acids, histamine, hydroxyindoleacetic acid, hydroxyproline, lactate, neonatal bilirubin (1 or more fractions), oxalate, pyruvate, serotonin, xylose, zinc—1 quantitative estimation | $24.00 |\n| | | |\n| 66275 | 2 or more estimations specified in item 66273 | $37.50 |\n\nSCHEDULE—continued\n\n| | | |\n| ----- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------ |\n| 66277 | Aluminium (except if item 66325 applies), arsenic, beryllium, cadmium, copper, chromium, gold, manganese, mercury, nickel, selenium, strontium, in blood, urine or other body fluid or tissue—1 or more estimations in any 6 month period | $34.50 |\n| | | |\n| 66279 | Blood lead estimation, other than for occupational health screening purposes, to a maximum of 3 estimations in any 6 month period—each estimation | $29.50 |\n| | | |\n| 66281 | Porphyrins (1 or more fractions), catecholamines (1 or more fractions), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), phenylacetic acid (PAA)—quantitative including any qualitative estimations—1 or more estimations | $38.50 |\n| | | |\n| 66283 | Faecal fat, breath hydrogen measurements in response to loading with disaccharides—1 or more quantitative estimations within any 28 day period | $38.50 |\n| | | |\n| 66285 | Solid tissue or tissues excluding blood elements—assay of 1 or 2 enzymes | $38.50 |\n| | | |\n| 66287 | Assay of 3 to 5 enzymes as specified in item 66285 | $72.00 |\n| | | |\n| 66289 | Assay of 6 or more enzymes as specified in item 66285 | $95.00 |\n| | | |\n| 66291 | Thyroid function tests, including thyrotrophin (TSH) and at least 1 or more of the following tests—free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin | $40.00 |\n| | | |\n| 66293 | Thyrotrophin releasing hormone (TRH) test, including provision and administration of TRH and all necessary estimations of hormones | $47.50 |\n| | | |\n| 66295 | Growth hormone suppression by glucose loading, growth hormone stimulation by exercise, dexamethasone suppression test, L-dopa stimulation of growth hormone, where physically performed by a recognised pathologist—1 or more procedures | $11.40 |\n| | | |\n\n \nSCHEDULE—continued\n\n| 66297 | Gonadotrophin releasing hormone stimulation test, synacthen stimulation test, glucagon stimulation test with C-peptide measurement, pentagastrin stimulation of thyrocalcitonin release, secretin stimulation of gastrin release, insulin hypoglycaemia, arginine infusion, where physically performed by a recognised pathologist—1 procedure | $38.00 |\n| ----- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------ |\n| | | |\n| 66299 | 2 or more tests specified in item 66297 | $60.00 |\n| | | |\n| 66301 | Hormones and hormone binding proteins, quantitative estimation by any method of—ACTH, aldosterone, androstenedione, C-peptide, calcitonin, cortisol, cyclic AMP, DHEAS, 11-deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, human placental lactogen, hydroxyprogesterone, insulin, LH, oestradiol, oestriol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(IgF1), free or total testosterone, TSH (where not requested as part of a thyroid function test), urine steroid fraction or fractions, vasoactive intestinal peptide, vasopressin (antidiuretic hormone)—1 estimation | $30.80 |\n| | | |\n| 66303 | 2 estimations specified in item 66301 | $41.60 |\n| | | |\n| 66305 | 3 estimations specified in item 66301 | $52.40 |\n| | | |\n| 66307 | 4 estimations specified in item 66301 | $63.20 |\n| | | |\n| 66309 | 5 estimations specified in item 66301 | $74.00 |\n| | | |\n| 66311 | 6 or more estimations specified in item 66301 | $84.80 |\n| | | |\n| 66313 | Estimations specified in any of items 66301 to 66311 (inclusive), if the number of estimations relating to the same patient episode does not exceed 6—each estimation to a maximum of 5 estimations | $10.80 |\n| | | |\n| 66315 | Hormone receptor assay on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast—1 or more assays | $77.00 |\n| | | |\n\n \nSCHEDULE—continued\n\n| 66317 | HDL cholesterol, or apolipoprotein B/A1 ratio, estimation of, in patients with serum cholesterol >5.5mmol/l or those on prescribed lipid lowering drugs or with a fasting serum triglyceride level > 2.0 mmol/1—each estimation to a maximum of 4 estimations in any 12 month period | $12.00 |\n| ----- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------ |\n| | | |\n| 66319 | Glycosylated haemoglobin only when performed in the management of established diabetes—each estimation to a maximum of 4 estimations in any 12 month period | $16.20 |\n| | | |\n| 66321 | Quantitative estimation in the 2nd trimester of pregnancy of alpha-fetoprotein, human chorionic gonadotrophin and oestriol and any other substance to detect foetal abnormality, including any service specified in 1 or more of items 66259, 66301, 73527 or 73529—1 patient episode in that pregnancy | $53.00 |\n| | | |\n| 66323 | Estimation of tryptic activity in faeces for the investigation of diarrhoea of greater than 4 weeks duration in children less than 6 years of age | $10.80 |\n| | | |\n| 66325 | Estimation of serum aluminium in a patient in a renal dialysis program—each estimation | $34.50 |\n| | | |\n| | | |\n| | GROUP P3 - MICROBIOLOGY | |\n| | | |\n| 69201 | Microscopic examination of material other than blood, from 1 or more sites, obtained directly from a patient and excluding material from cultures—wet film, including differential cell count if performed, examination for dermatophytes or dark ground illumination, or stained preparation or preparations using any relevant stain or stains—1 or more examinations | $7.20 |\n| | | |\n| 69203 | Microscopic examination of faeces for parasites using concentration techniques including the use of appropriate stains, to a maximum of 3 estimations taken on separate days including any services specified in item 69201—each estimation | $12.00 |\n| | | |\n\n \nSCHEDULE—continued\n\n| 69205 | The cultural examination and microscopical examination when indicated (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from nasal swabs, throat swabs, eye swabs and ear swabs, including pathogen identification and antibiotic sensitivity testing, including any services specified in item 69201—1 or more sites | $18.80 |\n| ----- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------ |\n| | | |\n| 69207 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from the following sites - skin or other superficial sites, urethra, vagina, cervix or rectum (except for faecal pathogens), or specimens of sputum (except when part of item 69213), including pathogenic identification and antibiotic sensitivity testing, including any services specified in items 69201 and 69205—1 or more examinations on 1 or more specimens | $27.50 |\n| | | |\n| 69209 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) of postoperative wounds, aspirations of body cavities, synovial fluid, CSF and operative or biopsy specimens for the presence of pathogenic micro-organisms, including fungi but excluding viruses, involving aerobic and anaerobic culture and the use of different culture media and including pathogen identification and antibiotic sensitivity testing, including any services specified in items 69201, 69205 and 69207—1 or more sites | $37.50 |\n| | | |\n| 69211 | Cultural examination (including the detection of clostridial toxins or antigens not elsewhere specified in the Schedule) of faeces to determine the presence or absence of faecal pathogens, involving the use of at least 2 selective or enrichment media as well as culture in at least 2 different atmospheres and includes pathogen identification and antibiotic sensitivity testing, including any services specified in item 69201, to a maximum of 3 specimens in any 7 day period—each examination | $45.50 |\n| | | |\n\n \nSCHEDULE—continued\n\n| 69213 | Microscopy with appropriate stains and cultural examinations of 3 specimens of sputum, urine or other bodily fluids for mycobacteria and any other bacterial pathogens, including pathogen identification and antibiotic sensitivity testing and including any services specified in item 69201 | $63.00 |\n| ----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------ |\n| | | |\n| 69215 | Blood culture to determine the presence or absence of pathogenic micro-organisms excluding viruses, including serial cultures and sub-cultures, any relevant cultural methods and any tests necessary to identify any cultured pathogen and necessary antibiotic sensitivity testing —each set of cultures to a maximum of 3 sets | $16.60 |\n| | | |\n| 69217 | Urine examination including serial examination, with cell count, relevant stained preparations, culture, colony count by any method, identification of any cultured pathogens, antibiotic sensitivity testing when necessary, and with any relevant general examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts (simple culture by dip slide is excluded from this item) | $20.10 |\n| | | |\n| 69219 | Direct detection of the antigens of Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Group B streptococcus (in CSF and urine specimens only), RSV, cryptococcal antigens and Varicella zoster or detection of Clostridium difficile toxin except where item 69211 has been performed—1 or more estimations | $15.80 |\n| | | |\n| 69221 | Direct detection of Chlamydia from clinical material, not cultures—1 or more estimations | $9.50 |\n| | | |\n| 69223 | Direct detection of herpes simplex virus from clinical material, not cultures—1 or more estimations | $9.50 |\n| | | |\n| 69225 | Investigation for herpes simplex virus (1 or more types) or Chlamydia trachomatis, in material obtained directly from a patient, by 1 or more cultural methods, including any services specified in items 69221 and 69223 | $27.50 |\n| | | |\n| 69229 | Antibodies to microbial or exogenous antigens not elsewhere specified in the Schedule—estimation of 1 antibody | $13.60 |\n| | | |\n| 69231 | 2 estimations specified in item 69229 | $20.80 |\n\nSCHEDULE—continued\n\n| | | |\n| ----- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------ |\n| 69233 | 3 estimations specified in item 69229 | $28.00 |\n| | | |\n| 69235 | 4 estimations specified in item 69229 | $35.20 |\n| | | |\n| 69237 | 5 estimations specified in item 69229 | $42.40 |\n| | | |\n| 69239 | 6 or more estimations specified in item 69229 | $49.60 |\n| | | |\n| 69241 | Estimations specified in any of items 69229 to 69239 (inclusive), if the number of estimations relating to the same patient episode does not exceed 6—each estimation to a maximum of 5 estimations | $7.20 |\n| | | |\n| 69243 | Hepatitis B surface antigen test | $13.40 |\n| | | |\n| 69245 | Hepatitis B serology to define the immune status of an individual, including at least hepatitis B surface antibody or hepatitis B core antibody tests, including services specified in items 69243, 69247 and 69249 | $18.20 |\n| | | |\n| 69247 | All serological tests performed for the identification of the agent causing acute hepatitis, which must include hepatitis B surface antigen, hepatitis B core antibody and hepatitis A IgM antibody tests and those services specified in items 69243, 69245 and 69249 | $36.00 |\n| | | |\n| 69249 | All tests performed in the follow up of a patient with proven hepatitis B, including hepatitis B surface antigen and either hepatitis B antigen or hepatitis B surface antibody tests, including services specified in items 69243 and 69245 | $26.00 |\n| | | |\n| 69251 | Antibiotics or antimicrobial chemotherapeutic agents, concentration in serum, urine or other body fluid, by direct quantitative measurement of the agent—1 or more estimations | $24.00 |\n| | | |\n| 69253 | All microbiological serology during a pregnancy, which must include the determination of 1 of the following—rubella immune status, specific syphilis serology or hepatitis B surface antigen—including any service specified in 1 or more of items 69229, 69243 or 69245, except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy | $13.60 |\n| | | |\n\nSCHEDULE—continued\n\n| 69255 | All microbiological serology during a pregnancy, which must include the determination of 2 of the following—rubella immune status, specific syphilis serology or hepatitis B surface antigen and including any service specified in 1 or more of items 69229, 69243 or 69245, except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy | $21.00 |\n| ----- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------- |\n| | | |\n| 69257 | All microbiological serology during a pregnancy, which must include the determination of all 3 of the following - rubella immune status, specific syphilis serology and hepatitis B surface antigen—including any service specified in 1 or more of items 69229, 69243 or 69245, except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy | $27.50 |\n| | | |\n| | | |\n| | GROUP P4 - IMMUNOLOGY | |\n| | | |\n| 71061 | Examination for, and characterisation of, a paraprotein or cryoglobulin not previously characterised on serum, urine or other body fluid by immunoelectrophoresis or immunofixation - 1 or more procedures | $28.00 |\n| | | |\n| 71063 | Examination for, and characterisation of, a paraprotein not previously characterised, by immunoelectrophoresis or immunofixation on serum and urine collected concurrently—2 or more procedures | $42.50 |\n| | | |\n| 71065 | Examination of CSF and serum concurrently for the presence of oligoclonal proteins—2 or more procedures | $42.50 |\n| | | |\n| 71067 | Immunoglobulins A, G, M or D, quantitative estimation by any method in serum, urine or other body fluid—1 estimation | $14.50 |\n| | | |\n| 71069 | 2 estimations as specified in item 71067 | $22.90 |\n| | | |\n| 71071 | 3 or more estimations as specified in item 71067 | $31.30 |\n| | | |\n| 71073 | Immunoglobulin G subclasses, quantitative estimation of all 4 subclasses with a maximum of 2 patient episodes in any 12 month period - each patient episode | $102.00 |\n| | | |\n\nSCHEDULE—continued\n\n| 71075 | Immunoglobulin E (total), quantitative estimation with a maximum of 2 patient episodes in any 12 month period—each patient episode | $26.00 |\n| ----- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------ |\n| | | |\n| 71077 | Immunoglobulin E (total), quantitative estimation in the follow up of a patient with proven immunoglobulin E secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis, with a maximum of 6 patient episodes in any 12 month period—each patient episode | $26.00 |\n| | | |\n| 71079 | Estimation of specific immunoglobulin G or E antibodies to single or multiple potential allergens, with a maximum of 4 patient episodes in any 12 month period—each patient episode | $23.50 |\n| | | |\n| 71081 | Total haemolytic complement, quantitative estimation | $19.40 |\n| | | |\n| 71083 | Complement components C3, C4 or properdin factor B, quantitative estimation —1 estimation | $19.40 |\n| | | |\n| 71085 | 2 estimations as specified in item 71083 | $27.90 |\n| | | |\n| 71087 | 3 or more estimations as specified in item 71083 | $36.40 |\n| | | |\n| 71089 | Complement components or breakdown products of complement proteins not elsewhere specified in an item in this Schedule, quantitative estimation—1 estimation | $28.10 |\n| | | |\n| 71091 | 2 estimations as specified in item 71089 | $50.90 |\n| | | |\n| 71093 | 3 or more estimations as specified in item 71089 | $73.70 |\n| | | |\n| 71097 | Antinuclear antibodies, detection in serum or other body fluids, including quantitation if required | $24.50 |\n| | | |\n| 71099 | Double-stranded DNA antibodies, quantitative estimation by 1 or more methods other than the Crithidia method | $25.50 |\n| | | |\n| 71101 | Antibodies to 1 or more extractable nuclear antigens, detection in serum or other body fluids | $16.80 |\n| | | |\n\n \nSCHEDULE—continued\n\n| 71103 | Antibodies to 1 or more extractable nuclear antigens, characterisation after a positive result is obtained by a service specified in item 71101, including that service | $50.00 |\n| ----- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------- |\n| | | |\n| 71105 | Rheumatoid factor, detection by any technique | $8.40 |\n| | | |\n| 71107 | Quantitation of rheumatoid factor if detected, during a service specified in item 71105, including that service | $19.40 |\n| | | |\n| 71109 | Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, cardiolipin, glomerular basement membrane, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, neutrophil cytoplasm, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome, thyroid stimulating hormone receptor), qualitative or quantitative—estimation of 1 antibody | $33.30 |\n| | | |\n| 71113 | Estimation of 2 antibodies specified in item 71109 | $50.00 |\n| | | |\n| 71115 | Estimation of 3 antibodies specified in item 71109 | $62.30 |\n| | | |\n| 71117 | Estimation of 4 antibodies specified in item 71109 | $70.60 |\n| | | |\n| 71119 | Antibodies to tissue antigens not elsewhere specified in an item in this Schedule, qualitative or quantitative—estimation of 1 antibody | $16.70 |\n| | | |\n| 71121 | Estimation of 2 antibodies specified in item 71119 | $20.00 |\n| | | |\n| 71123 | Estimation of 3 antibodies specified in item 71119 | $23.30 |\n| | | |\n| 71125 | Estimation of 4 or more antibodies specified in item 71119 | $26.60 |\n| | | |\n| 71127 | Functional tests for lymphocytes—estimation of proliferation induced by 1 or more mitogens, estimation of proliferation induced by 1 or more antigens or estimation of 1 or more mixed lymphocyte reactions, other than quantitation by microscopy—including a test specified in item 65005, with a maximum of 2 patient episodes in any 12 month period—each patient episode | $170.00 |\n| | | |\n| 71129 | 2 estimations specified in item 71127 | $210.00 |\n\nSCHEDULE—continued\n\n| | | |\n| ----- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------- |\n| 71131 | 3 or more estimations specified in item 71127 | $250.00 |\n| | | |\n| 71135 | Determination of neutrophil function - comprising at least 2 of neutrophil chemotaxis, neutrophil phagocytosis, neutrophil oxidative metabolism, neutrophil bactericidal activity—including any test specified in item 65005 (other than nitroblue tetrazolium reduction slide test), with a maximum of 2 patient episodes in any 12 month period—each patient episode | $200.00 |\n| | | |\n| 71137 | Determination of cell mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7 antigens, with a maximum of 2 patient episodes in any 12 month period—each patient episode | $29.00 |\n| | | |\n| 71139 | Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more specimens of blood, CSF or serous fluid | $100.00 |\n| | | |\n| 71141 | Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimens | $220.00 |\n| | | |\n| 71143 | Characterisation (not monitoring) of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations in an immunological or haematological malignancy, including any service specified in 1 or more of items 71139 or 71141, on a specimen of blood, CSF, serous fluid or disaggregated tissue | $250.00 |\n| | | |\n| 71145 | Characterisation (not monitoring) of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations in an immunological or haematological malignancy, including any service specified in 1 or more of items 71139, 71141 or 71143, on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluid | $410.00 |\n| | | |\n| 71147 | HLA-B27 typing | $33.50 |\n| | | |\n\nSCHEDULE—continued\n\n| 71149 | Complete tissue typing for 4 HLA-A and HLA-B Class I antigens (including any separation of leucocytes), including any service specified in item 71147 | $104.00 |\n| ----- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------- |\n| | | |\n| 71151 | Tissue typing for HLA-DR, HLA-DP and HLA-DQ Class II antigens (including any separation of leucocytes)—phenotyping or genotyping of 2 or more antigens | $114.00 |\n| | | |\n| | | |\n| | GROUP P5 - HISTOPATHOLOGY | |\n| | | |\n| 72801 | Histopathology examination of biopsy material including all tissue processing, staining and professional opinion or opinions | $77.00 |\n| | | |\n| 72803 | Immediate frozen section diagnosis of biopsy material, including any other histopathology examination | $126.00 |\n| | | |\n| 72805 | Immunohistochemical investigation of biopsy material by 1 or more of immunofluorescent, immunoperoxidase or other labelled antibody techniques including any other histopathology examination | $95.00 |\n| | | |\n| 72807 | Electron microscopy of biopsy material including any other histopathology examination | $102.00 |\n| | | |\n| | | |\n| | GROUP P6 - CYTOPATHOLOGY | |\n| | | |\n| 73043 | Cytological examination including serial examinations of smears from skin, nipple discharge, lip, mouth, nose or anus for detection of precancerous or cancerous changes—1 or more examinations | $14.60 |\n| | | |\n| 73045 | Cytological examination, other than an examination mentioned in item 73053, for malignancy, including serial examinations and histological services performed on the resulting specimens from washings or brushings from sites not specified in item 73043, or performed on a single specimen of sputum or urine or on 1 or more specimens of other body fluids—1 or more examinations | $28.50 |\n| | | |\n| 73047 | Cytological examination including examination of a series of 3 sputum or urine specimens for malignant cells | $60.00 |\n| | | |\n\nSCHEDULE—continued\n\n| 73049 | Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues | $36.00 |\n| ----- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------ |\n| | | |\n| 73051 | Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues where the aspiration is performed by a recognised pathologist; or where a recognised pathologist attends the aspiration and performs cytological examination during the attendance | $67.00 |\n| | | |\n| 73053 | Routine cytological examination of smears from cervix for detection of precancerous or cancerous changes in women with no symptoms, signs or recent history suggestive of cervical neoplasia and smears repeated due to an unsatisfactory routine smear—each examination | $12.20 |\n| | | |\n| 73055 | Cytological examination of smears from cervix in association with the management of previously detected abnormalities including precancerous or cancerous conditions, or the investigation of women with symptoms, signs or recent history suggestive of cervical neoplasia, not associated with item 73053—each examination | $12.20 |\n| | | |\n| 73057 | Cytological examination of smears from vagina, not associated with items 73053 or 73055—each examination | $12.20 |\n| | | |\n\n| | GROUP P7 - CYTOGENETICS | |\n| ----- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------- |\n| | | |\n| 73281 | Chromosome studies, including preparation, count and karyotyping of 1 or more of amniotic fluid, bone marrow, skin and any other tissue or fluid excluding blood—1 or more estimations | $130.00 |\n| | | |\n| 73283 | Chromosome studies, including preparation, count and karyotyping of blood | $118.00 |\n| | | |\n| 73285 | Chromosome identification by banding techniques (using fluorescein, Giemsa, or centromere staining or high resolution analysis); or by fragile X-site determination—1 or more identifications | $102.00 |\n| | | |\n\n \nSCHEDULE—continued\n\n| | | |\n| ----- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------ |\n| | GROUP P8 - INFERTILITY AND PREGNANCY TESTS | |\n| | | |\n| 73521 | Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner's test) | $6.60 |\n| | | |\n| 73523 | Semen examination (excluding post vasectomy semen examination), involving measurement of volume, sperm count, motility, examination of stained preparations, morphology, and, if performed, differential count and 1 or more chemical tests, with a maximum of 4 examinations in any 12 month period | $27.50 |\n| | | |\n| 73525 | Sperm antibodies, sperm penetrating ability—1 or more tests | $17.80 |\n| | | |\n| 73527 | Chorionic gonadotrophin (beta-HCG), qualitative estimation in serum or urine by 1 or more methods, including serial dilution if performed, for diagnosis of pregnancy —1 or more estimations | $9.70 |\n| | | |\n| 73529 | Chorionic gonadotrophin (beta-HCG), qualitative (if performed) and quantitative estimation in serum by 1 or more methods for diagnosis of hydatidiform mole, HCG—secreting neoplasm, threatened abortion or follow up of abortion | $27.50 |\n| | | |\n| | | |\n| | GROUP P9 - SIMPLE BASIC PATHOLOGY TESTS | |\n| | | |\n| 73801 | Seminal examination for presence of spermatozoa | $6.30 |\n| | | |\n| 73802 | Blood count consisting of leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count) or any or all of haemoglobin estimation, haematocrit estimation or erythrocyte count—1 procedure | $4.20 |\n| | | |\n| 73803 | 2 procedures specified in item 73802 | $6.30 |\n| | | |\n| 73804 | 3 or more procedures specified in item 73802 | $8.40 |\n| | | |\n| 73805 | Microscopical examination of urine | $4.20 |\n| | | |\n| 73806 | Pregnancy test by 1 or more immunochemical methods | $10.40 |\n| | | |\n| 73807 | Microscopical examination of wet film other than urine | $6.30 |\n\nSCHEDULE—continued\n\n| | | |\n| ----- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------ |\n| 73808 | Microscopical examination of gram stained film | $8.00 |\n| | | |\n| 73809 | Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method | $2.10 |\n| | | |\n| 73810 | Microscopical examination screening for fungi in skin, hair or nails —1 or more sites | $6.30 |\n| | | |\n| 73811 | Mantoux test | $10.40 |\n| | | |\n| | | |\n| | GROUP P10 - PATIENT EPISODE INITIATION | |\n| | | |\n| 73901 | Initiation of a patient episode which consists only of a service specified in item 73053, 73055 or 73057 from a person who is not in a recognised hospital or a prescribed laboratory | $7.70 |\n| | | |\n| 73903 | Initiation of a patient episode which consists only of a service specified in item 72801 from a person who is an in-patient of a hospital other than a recognised hospital | $13.80 |\n| | | |\n| 73905 | Initiation of a patient episode which consists only of a service specified in item 72801 from a person who is not an in-patient of a private hospital and not a patient of a recognised hospital | $7.70 |\n| | | |\n| 73907 | Initiation of a patient episode by collection of specimen for a service other than a service specified in items 73901, 73903, 73905 and 73801 to 73811 (inclusive) where the specimen is collected in a licensed collection centre other than a temporary licensed collection centre | $15.80 |\n| | | |\n| 73909 | Initiation of a patient episode by collection of specimen for a service other than a service specified in items 73901, 73903, 73905 and 73801 to 73811 (inclusive) where the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person who is an in-patient of a hospital other than a recognised hospital | $15.80 |\n| | | |\n\n \nSCHEDULE—continued\n\n| 73911 | Initiation of a patient episode by collection of specimen for a service other than a service specified in items 73901, 73903, 73905 and 73801 to 73811 (inclusive) where the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority, from a person in the place where the person was residing or in a nursing home or institution | $15.80 |\n| ----- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------ |\n| | | |\n| 73913 | Initiation of a patient episode by collection of specimen for a service other than a service specified in items 73901, 73903, 73905, 73907, 73917 and 73801 to 73811 (inclusive) where the specimen is collected from the person by the person | $9.70 |\n| | | |\n| 73915 | Initiation of a patient episode by collection of specimen for a service other than a service specified in items 73901, 73903, 73905 and 73801 to 73811 (inclusive) where the specimen is collected by or on behalf of the treating practitioner | $9.70 |\n| | | |\n| 73917 | Initiation of a patient episode by collection of specimen for a service other than a service specified in items 73901, 73903, 73905 and 73801 to 73811 (inclusive) where the specimen is collected in a temporary licensed collection centre | $9.70 |\n| | | |\n| | | |\n| | GROUP P11 - SPECIMEN REFERRED | |\n| | | |\n| 73921 | Referral of specimen by an approved pathology practitioner of an approved pathology authority to another approved pathology practitioner of another approved pathology authority or to another approved pathology authority | $9.70 |\n| | | |\n| | | |\n\n \nSCHEDULE—continued\n\nABBREVIATIONS\n\nA. ABBREVIATIONS FOR GROUPS OF TESTS\n\nEstimations\n\nGroup Included in Group Abbreviation Item Numbers\n\nCardiac Lactate dehydrogenase (LDH) CE 66205\n\nEnzymes aspartate aminotransferase\n\n(AST) and\n\ncreatine kinase (CK)\n\nCoagulation Prothrombin time, COAG 65035\n\nStudies activated partial thrombo-\n\nplastin time and two or\n\nmore of the following tests-\n\nbleeding time, thrombin\n\nclotting time, fibrinogen\n\ndegradation products,\n\nfibrin monomer, D-dimer,\n\nfactor XIII screening tests\n\nElectrolytes Sodium (NA) E 66207\n\npotassium (K)\n\nchloride (CL) and\n\nbicarbonate (HCO3)\n\nLipid Studies Cholesterol (CHOL) and FATS 66203\n\ntriglycerides (TRIG)\n\nLiver Function Alkaline phosphatase (ALP), LFT 66211\n\nTests alanine aminotransferase\n\n(ALT),\n\naspartate aminotransferase\n\n(AST),\n\nalbumin (ALB),\n\nbilirubin (BIL),\n\ngamma glutamyl\n\ntranspeptidase (GGT),\n\nlactate dehydrogenase (LDH),\n\nand protein (PROT)\n\nSCHEDULE—continued\n\nSyphilis Rapid plasma reagin test STS 69231\n\nSerology (RPR) or venereal disease\n\nresearch laboratory\n\ntest (VDRL) and\n\ntreponema pallidum\n\nhaemagglutination test (TPHA)\n\nor fluorescent treponemal\n\nantibody-absorption test\n\n(FTA)\n\nUrea, Urea, U&E 66211\n\nElectrolytes, electrolytes,\n\nCreatine creatinine\n\nB. ABBREVIATIONS FOR INDIVIDUAL TESTS\n\nAbnormal haemoglobins AH 65027\n\nAcetoacetate ACAT 66273\n\nAdrenocorticotrophic hormone (ACTH) ACTH 66301\n\nAFB microscopy & culture of sputum AFB 69213\n\nAlanine aminotransferase ALT 66201\n\nAlbumin ALB 66201\n\nAlcohol (ethanol) ETOH 66273\n\nAldosterone ALDS 66301\n\nAlkaline phosphatase ALP 66201\n\n\\- isoenzymes ALPI 66245\n\nAlpha fetoprotein AFP 66259\n\n\\- for Down syndrome testing NTDD 66321\n\nAlpha-1-antitrypsin AAT 66255\n\nAlpha-1-acid glycoprotein AAG 66255\n\nAlpha-2-macroglobulin AMG 66255\n\nAluminium AL 66277\n\n\\- renal dialysis ALR 66325\n\nAmino acids AA 66273\n\nAmiodarone AMIO 66235\n\nAmitriptyline AMIT 66235\n\nAmmonia NH3 66273\n\nAmniotic fluid examination AFE 66243\n\nAmylase AMS 66201\n\nAmylobarb AMYL 66235\n\nAndrostenedione ANDR 66301\n\nAngiotensin converting enzyme ACE 66273\n\nAntibiotic & antimicrobial chemotherapeutic agents,\n\nquantitative assay QAA 69251\n\nSCHEDULE—continued\n\nAntibodies to\n\n\\- extractable nuclear antigens\n\n\\- detection ENA 71101\n\n\\- characterisation of antibodies if positive ENA ENAP 71103\n\n\\- nuclear antigens\n\n\\- detection ANA 71097\n\n\\- quantitation & measurement of DNA\n\nbinding if positive ANA ANAP 71099\n\n\\- tissue antigens\n\n\\- acetylcholine receptor ARA 71109\n\n\\- adrenal cortex ADR 71109\n\n\\- cardiolipin ACL 71109\n\n\\- centromere ACA 71119\n\n\\- gastric parietal cell PCA 71119\n\n\\- gliadin IgA GLIA 71119\n\n\\- glomerular basement membrane GBA 71109\n\n\\- heart AHE 71109\n\n\\- histone AHI 71109\n\n\\- insulin AINS 71109\n\n\\- insulin receptor antibodies INSA 71109\n\n\\- intercellular cement substance of skin ICCS 71109\n\n\\- intrinsic factor AIF 71109\n\n\\- islet cell AIC 71109\n\n\\- Jo-1 JO1 71119\n\n\\- keratin KERA 71119\n\n\\- liver/kidney microsomes LKA 71119\n\n\\- lymphocyte ALY 71109\n\n\\- mitochondria MA 71119\n\n\\- neuron ANE 71109\n\n\\- neutrophil cytoplasm ANCA 71109\n\n\\- ovary AOV 71109\n\n\\- parathyroid PTHA 71109\n\n\\- platelet APA 71109\n\n\\- PM-Sc1 PM1 71119\n\n\\- reticulin RCA 71119\n\n\\- salivary gland ASG 71109\n\n\\- Scl-70 SCL 71119\n\n\\- skeletal muscle SLA 71109\n\n\\- skin basement membrane SKA 71109\n\n\\- smooth muscle SMA 71119\n\n\\- thyroglobulin ATG 71109\n\n\\- thyroid microsome TMA 71109\n\n\\- TSH receptor antibody test TSHA 71109\n\nAntibody testing, microbial (see Microbial)\n\nSCHEDULE—continued\n\nAntigen testing, microbial (see Microbial)\n\nAntithrombin III ATH 65037\n\nApolipoprotein B/A1 ratio APO 66317\n\nArginine infusion ARIN 66297\n\nArsenic AS 66277\n\nAspartate aminotransferase AST 66201\n\nBarbiturate BARB 66235\n\nBeryllium BE 66277\n\nBeta-hydroxybutyrate BHYB 66273\n\nBeta-2-microglobulin BMIC 66259\n\nBicarbonate HCO3 66201\n\nBilirubin (all fractions) BILI 66201\n\n\\- neonatal BILN 66273\n\nBleeding time BT 65029\n\nBlood\n\n\\- compatability testing XMAT 65023\n\n\\- culture BC 69215\n\n\\- film BF 65005\n\n\\- full examination FBE 65001\n\n\\- gases GAS 66225\n\n\\- group & blood group antibodies BGAB 65021\n\n\\- group antibodies BGA 65025\n\n\\- group systems BGS 65019\n\n\\- grouping-ABO & RH (D antigen) BG 65017\n\n\\- viscosity VISC 65001\n\nBone marrow examination\n\n\\- aspirate BMEA 65015\n\n\\- trephine BMET 65013\n\nBreath hydrogen test BHT 66283\n\nBromide BRMD 66235\n\nC-l esterase inhibitor\n\n\\- quantitative CEIQ 66257\n\n\\- functional CEIF 66258\n\nC-Peptide CPEP 66301\n\nC-reactive protein CRP 65001\n\nCA-15.3 antigen CA15 66261\n\nCA-l9.9 antigen CA19 66261\n\nCA-125 antigen C125 66261\n\nCadmium CD 66277\n\nCaeruloplasmin CPLS 66259\n\nCalcitonin CALT 66301\n\nCalcium (total, dialysed or ionized) CA 66201\n\nCalculus analysis CALC 66229\n\nCarbamazepine (Tegretol) CARB 66235\n\nSCHEDULE—continued\n\nCarboxyhaemaglobin COHB 65027\n\nCarcinoembryonic antigen CEA 66261\n\nCatecholamines CAT 66281\n\nChlamydia\n\n\\- direct detection from clinical material CHLY 69221\n\n\\- investigation by cultural methods CHLC 69225\n\nChloral hydrate CHHY 66235\n\nChlorazepate CHZP 66235\n\nChloride CL 66201\n\nChloroquine CLOQ 66235\n\nChlorpromazine CHLO 66235\n\nCholesterol CHOL 66201\n\n\\- HDL HDLC 66317\n\nCholinesterase CHSE 66273\n\nChorionic gonadotrophin\n\n\\- for pregnancy diagnosis HCG 73527\n\n\\- for diagnosis of specified conditions HCGD 73529\n\n\\- for Down syndrome testing NTDD 66321\n\nChromium CR 66277\n\nChromosome identification\n\n\\- by banding technique CSI 73285\n\n\\- studies CS 73281\n\n\\- studies of blood CSB 73283\n\nCimetidine CMTD 66235\n\nClobazam CLOB 66235\n\nClomipramine CLOM 66235\n\nClonazepam (Rivotril) CLON 66235\n\nClostridium difficile CLDT 69219\n\nCoagulation\n\n\\- factors (see individual factors)\n\n\\- time CT 65029\n\nCold agglutinins CAG 65005, 65027\n\nCompatability testing XMAT 65023\n\nComplement, total haemolytic COM 71081\n\n\\- components C3 C3 71083\n\n\\- components C4 C4 71083\n\n\\- properdin factor B PFB 71083\n\n\\- other components COMP 71089\n\nCopper CU 66277\n\nCortisol CORT 66301\n\nCreatine kinase CK 66201\n\n\\- isoenzymes CKI 66201\n\n\\- isoenzymes (electrophoresis) CKIE 66245\n\nCreatinine C 66201\n\nSCHEDULE—continued\n\nCryofibrinogen\n\n\\- qualitative CFID 66213\n\n\\- quantitative CFIE 66215\n\nCryoglobulins\n\n\\- qualitative CGLD 66213\n\n\\- quantitative CGLE 66215\n\n\\- investigation by immunoelectrophoresis\n\nor immunofixation CRYO 71061\n\nCryptococcal antigen CRYN 69219\n\nCSF antigens\n\n\\- Haemophilus influenzae HI 69219\n\n\\- Streptoccus pneumoniae SPN 69219\n\n\\- Neisseria meningitidis NMG 69219\n\n\\- group B streptococcus STB 69219\n\nCultural examination of faeces FCS 69211\n\nCylic AMP CAMP 66301\n\nCyclosporin A CLSA 66235\n\nCystine (cysteine)\n\n\\- qualitative UCYS 66213\n\n\\- quantitative CYST 66273\n\nCytology\n\n\\- from body fluids, sputum (1 specimen),\n\nurine, washings or brushings BFCY 73045\n\n\\- from cervix\n\n\\- routine CCR 73053\n\n\\- abnormalities CCRA 73055\n\n\\- from fine needle aspiration of solid tissues FNCY 73049\n\n\\- aspiration or attendance by a pathologist FNCP 73051\n\n\\- from skin, nipple discharge, lip, mouth, nose or anus SMCY 73043\n\n\\- from vagina CVO 73057\n\n\\- from 3 sputum or urine specimens SPCY 73047\n\nD-dimer test DD 65029\n\nDehydroepiandrosterone sulphate DHEA 66301\n\nDeoxycortisol DCOR 66301\n\nDesipramine DESI 66235\n\nDexamethasone DXST 66295\n\n\\- suppression test DEXA 66301\n\nDiazepam DIAZ 66235\n\nDifferential cell count DIFF 65005\n\nDigoxin DIG 66235\n\nDihydrotesterone DHTS 66301\n\nDiphenylhydantoin (Dilantin) DIL 66235\n\nDirect Coombs test CMBS 65005, 65027\n\nDisopyramide (Rythmodan) DISO 66235\n\nSCHEDULE—continued\n\nDNA, double-stranded antibodies DNAD 71099\n\nDown syndrome/neural tube defects NTDD 66321\n\nDoxepin hydrochloride DOXE 66235\n\nDrugs\n\n\\- inappropriate dosage - assay DRGO 66231\n\nElectron microscopy of biopsy material EM 72087\n\nElectrophoresis, to demonstrate\n\n\\- creatine kinase isoenzymes CKIE 66245\n\n\\- lactate dehydrogenase isoenzymes LDI 66245\n\n\\- protein classes, or paraprotein EPP1 66245\n\n\\- protein classes or presence & amount of\n\nparaprotein classes, concurrent collection EPP2 66247\n\nElements (see individual elements)\n\nEnzyme assays of solid tissue or tissues ENZS 66285\n\nErythrocyte\n\n\\- assessment of haemolysis ERYH 65009\n\n\\- assessment of metabolic enzymes ERYM 65009\n\n\\- count RCC 65001\n\n\\- sedimentation rate ESR 65001\n\nEthosuximide (Zarontin) ETHO 66235\n\nEuglobulin clot lysis time ECLT 65037\n\nFactor\n\n\\- II FII 65045\n\n\\- V FV 65045\n\n\\- VII FVII 65045\n\n\\- VIII VIII 65045\n\n\\- IX FIX 65045\n\n\\- X FX 65045\n\n\\- XI FXI 65045\n\n\\- XII FXII 65045\n\n\\- XIII XIII 65045\n\n\\- XIII deficiency test F13D 65029\n\nFaecal fat FFAT 66283\n\n\\- haemoglobin (chemical test) FHC 66217\n\n\\- haemoglobin (immunological test) FHI 66219\n\n\\- porphyrins (qualitative test) FPR 66217\n\n\\- reducing substances FRS 66217\n\nFaeces\n\n\\- cultural examination FCS 69211\n\n\\- microscopic examination for parasites OCP 69203\n\nFerritin (see also Iron studies) FERR 66259\n\nFibrin monomer FM 65029\n\nFibrinogen FIB 65029\n\n\\- degradation products FDP 65029\n\nSCHEDULE—continued\n\nFitzgerald factor FGF 65045\n\nFlecainide FLEC 66235\n\nFletcher factor FF 65045\n\nFluoxetine FLUX 66235\n\nFollicle stimulating hormone FSH 66301\n\nFrozen section diagnosis of biopsy material FS 72803\n\nFructosamine FRUC 66201\n\nFull blood examination FBE 65007\n\nGamma glutamyl transpeptidase GGT 66201\n\nGastrin GAST 66301\n\nGlobulin GLOB 66201\n\nGlucagon GLGO 66301\n\nGlucagon stimulation test GSTC 66297\n\nGlucose GLUC 66201\n\n\\- tolerance test GTT 66201\n\nGlycated haemoglobin (Hb Alc) GHB 66319\n\nGold AU 66277\n\nGonadotrophin GRHS 66297\n\nGroup B streptococcus antigens STB 69219\n\nGrowth hormone GH 66301\n\n\\- stimulation by exercise or L-dopa GHSE 66295\n\n\\- suppression by dexamethasone or glucose GHSG 66295\n\nHaematocrit HCT 65001\n\nHaemoglobin estimation HB 65001\n\nHaemoglobinopathy tests HMGP 65011\n\nHaemophilus influenzae antigens HI 69219\n\nHaloperidol HALO 66235\n\nHaptoglobins HGLB 66259\n\nHDL cholesterol HDLC 66317\n\nHeparin\n\n\\- cofactor II HRNC 65037\n\n\\- estimation HEPR 65043\n\nHepatitis serology\n\n\\- acute hepatitis HEP 69247\n\n\\- follow-up of proven hepatitis B HEPB 69249\n\n\\- hepatitis B serology to define immune status HEP1 69245\n\n\\- hepatitis B surface antigen HBsAg HBSA 69243\n\n\\- in pregnancy HEPP 69253-57\n\n\\- hepatitis C HEPC 69229\n\n\\- hepatitis delta antibody HDA 69229\n\nHerpes simplex virus\n\n\\- direct detection from clinical material HSV 69223\n\n\\- investigation by cultural methods HSVC 69225\n\nHeterophile antibodies IM 65005, 65027\n\nSCHEDULE—continued\n\nHIAA (hydroxyindoleacetic acid) HIAA 66273\n\nHistamine HIAM 66273\n\nHistopathology of biopsy material HIST 72801\n\nHLA typing\n\n\\- HLA-B27 HLAB 71147\n\n\\- HLA class 1 HLA1 71149\n\n\\- HLA class 2 HLA2 71151\n\nHMMA (hydroxy-3-methoxymandelic acid HMMA 66281\n\npreviously known as VMA)\n\nHMPG (hydroxy methoxy phenylethylene glycol) HMPG 66281\n\nHomovanillic acid HVA 66281\n\nHormone receptor assay\n\n\\- breast HRA 66315\n\n\\- ovary HRO 66315\n\nHormones:\n\n\\- adrenocorticotrophic hormone ACTH 66301\n\n\\- aldosterone ALDS 66301\n\n\\- androstanedione ANDR 66301\n\n\\- C-Peptide CPEP 66301\n\n\\- calcitonin CALT 66301\n\n\\- cortisol CORT 66301\n\n\\- cyclic AMP CAMP 66301\n\n\\- dehydroepiandrosterone sulphate DHEA 66301\n\n\\- dihydrotestosterone DHTS 66301\n\n\\- follicle stimulating hormone FSH 66301\n\n\\- gastrin GAST 66301\n\n\\- glucagon GLGO 66301\n\n\\- gonadotrophin GRHS 66297\n\n\\- growth hormone GH 66301\n\n\\- stimulation by exercise or L-dopa GHSE 66295\n\n\\- suppression by dexamethasone or glucose GHSG 66295\n\n\\- hormone receptor assay\n\n\\- breast HRA 66315\n\n\\- ovary HRO 66315\n\n\\- human placental lactogen HPL 66301\n\n\\- hydroxyprogesterone OHP 66301\n\n\\- insulin INS 66301\n\n\\- insulin, hypoglycaemia test INHY 66297\n\n\\- luteinizing hormone LH 66301\n\n\\- oestradiol E2 66301\n\n\\- oestriol E3 66301\n\n\\- oestrone E1 66301\n\n\\- parathyroid hormone PTH 66301\n\n\\- pentagastrin PSTR 66297\n\nSCHEDULE—continued\n\n\\- progesterone PROG 66301\n\n\\- prolactin PROL 66301\n\n\\- renin REN 66301\n\n\\- sex hormone binding globulin SHBG 66301\n\n\\- somatomedin SOMA 66301\n\n\\- testosterone TES 66301\n\n\\- thyroid stimulating hormone\n\n(where not requested as part of TFTs) TSH 66301\n\n\\- urine steroid fraction or fractions USF 66301\n\n\\- vasoactive intestinal peptide VIP 66301\n\n\\- vasopressin ADH 66301\n\n\\- 11 deoxycortisol DCOR 66301\n\nHuhner's test HT 73521\n\nHuman placental lactogen HPL 66301\n\nHVA (homovanillic acid) HVA 66281\n\nHydroxy methoxy phenylethylene glycol HMPG 66281\n\nHydroxy-3-methoxymandelic acid (previously\n\nknown as VMA) HMMA 66281\n\nHydroxychloroquine HOCQ 66235\n\nHydroxyindoleacetic acid HIAA 66273\n\nHydroxyprogesterone OHP 66301\n\nHydroxyproline HYDP 66273\n\nImipramine IMIP 66235\n\n\\- imediate frozen section diagnosis of biopsy material FS 72803\n\nImmunoglobulins\n\n\\- A IGA 71067\n\n\\- D IGD 71067\n\n\\- E (total) IGE 71075-77\n\n\\- G IGG 71067\n\n\\- G, 4 subclasses SIGG 71073\n\n\\- M IGM 71067\n\nImmunohistochemical investigation of biopsy material IHIS 72805\n\nInsulin INS 66301\n\nInsulin, hypoglycaemia test INHY 66297\n\nIntestinal disaccharidases INTD 66285\n\nIron (see Iron studies)\n\nIron studies (iron, transferrin & ferritin) IS 66263\n\nL-dopa GHLD 66295\n\nLactate LACT 66273\n\n\\- dehydrogenase LDH 66201\n\n\\- dehydrogenase isoenzymes LDI 66245\n\nLamellar body phospholipid LBPH 66243\n\nLead PB 66279\n\nLecithin/sphingomyelin ratio (amniotic fluid) LS 66243\n\nSCHEDULE—continued\n\nLeucocyte\n\n\\- count WCC 65001\n\n\\- 3 surface markers\n\n\\- blood, CSF, serous fluid LMH3 71139\n\n\\- tissue LMT3 71141\n\n\\- 6 surface markers\n\n\\- blood, CSF, serous fluid or tissue LM6 71143\n\n\\- blood, CSF, serous fluid & tissue (s) LMHT 71145\n\nLignocaine LIGN 66235\n\nLipoprotein electrophoresis LEPG 66245\n\nLipase LIP 66201\n\nLithium LI 66201\n\nLupus anticoagulant LUPA 65037\n\nLuteinizing hormone LH 66301\n\nLymphocytes\n\n\\- functional tests\n\n\\- 1 estimation LF1 71127\n\n\\- 2 estimations LF2 71129\n\n\\- 3 estimations LF3 71131\n\nMagnesium MG 66201\n\nMammary serum antigen MSA 66261\n\nManganese MN 66277\n\nMantoux test MANT 73811\n\nMelanogen (see Urine melanin) UML 66213\n\nMercury HG 66277\n\nMetalbumin detection (Schumm's test) SCHM 65027\n\nMetadrenalines MNEP 66281\n\nMethadone MTDN 66235\n\nMethotrexate MTTA 66235\n\nMethsuximide MSUX 66235\n\nMetronidazole MRDZ 66235\n\nMexiletine (Mexitil) MEX 66235\n\nMianserin MIAS 66235\n\nMicroalbumin MALB 66259\n\nMicrobial antibody testing\n\n\\- actinomycetes ACT 69229\n\n\\- adenovirus ADE 69229\n\n\\- aspergillus ASP 69229\n\n\\- avian precipitins (bird fancier's disease) APP 69229\n\n\\- Blastomyces BLM 69229\n\n\\- Bordetella pertussis BOR 69229\n\n\\- Borrelia burgdorferi BOB 69229\n\n\\- Brucella BRU 69229\n\n\\- Campylobacter jejuni CAM 69229\n\nSCHEDULE—continued\n\n\\- Candida CAN 69229\n\n\\- Chlamydia CHL 69229\n\n\\- Coccidioides CCC 69229\n\n\\- Coxsackie B1-6 COX 69229\n\n\\- cryptococus CRY 69229\n\n\\- cytomegalovirus CMV 69229\n\n\\- cytomegalovirus serology in pregnancy CMVP 69253-57\n\n\\- dengue DEN 69229\n\n\\- diphtheria DIP 69229\n\n\\- echinococcus ECC 69299\n\n\\- echo-coxsackie group ECH 69229\n\n\\- Entamoeba histolytica AMO 69229\n\n\\- Epstein Barr virus EBV 69229\n\n\\- fluorescent treponemal antibody\n\nabsorption test (FTA-ABS) FTA 69229\n\n\\- Haemophilus influenzae HUS 69229\n\n\\- hepatitis delta antibody - anti-delta HDA 69229\n\n\\- herpes HPA 69229\n\n\\- Histoplasma HIP 69229\n\n\\- hydatid HYD 69229\n\n\\- influenza A FLA 69229\n\n\\- influenza B FLB 69229\n\n\\- Legionella pneumophila - serogroup 1 LP1 69229\n\n\\- Legionella pneumophila - serogroup 2 LP2 69229\n\n\\- leishmaniasis LEI 69229\n\n\\- Leptospira LEP 69229\n\n\\- Listeria LIS 69229\n\n\\- measles MEA 69229\n\n\\- Micropolyspora faeni MIC 69229\n\n\\- mumps MUM 69229\n\n\\- Murray Valley encephalitis MVE 69229\n\n\\- Mycoplasma pneumoniae MYC 69229\n\n\\- Neisseria menigitidis MEN 69229\n\n\\- Newcastle disease NCD 69229\n\n\\- parainfluenza 1 PF1 69229\n\n\\- parainfluenza 2 PF2 69229\n\n\\- parainfluenza 3 PF3 69229\n\n\\- paratyphi PTY 69229\n\n\\- pertussis PER 69229\n\n\\- poliomyelitis PLO 69229\n\n\\- Proteus OX 19 POX 69229\n\n\\- Proteus OXK POK 69229\n\n\\- Q fever QFF 69229\n\n\\- rapid plasma reagin test RPR 69229\n\nSCHEDULE—continued\n\n\\- respiratory syncytial virus RSV 69229\n\n\\- Ross River virus RRV 69229\n\n\\- rubella RUB 69229\n\n\\- Salmonella typhi (H) SAH 69229\n\n\\- Salmonella typhi (O) SAO 69229\n\n\\- Schistosoma STO 69229\n\n\\- streptococcal serology - anti-\n\nDNASE B titre ADNB 69229\n\n\\- streptococcal serology-anti-streptolysin O titre ASOT 69229\n\n\\- Streptococcus pneumoniae PCC 69229\n\n\\- tetanus TET 69229\n\n\\- Thermoactinomyces vulgaris THE 69229\n\n\\- thermopolyspora TPS 69229\n\n\\- Toxocara TOC 69229\n\n\\- toxoplasma TOX 69229\n\n\\- TPHA(Treponema pallidum haemagglutin.test) TPHA 69229\n\n\\- Treponema pallidum haemagglutination test TPHA 69229\n\n\\- trichinosis TOS 69229\n\n\\- typhus, Weil-Felix TYP 69229\n\n\\- Varicella zoster VCZ 69229\n\n\\- VDRL (Venereal Disease Research Laboratory) VDRL 69229\n\n\\- Yersinia enterocolitica YER 69229\n\nMicrobial antigen testing\n\n\\- Chlamydia CHLY 69221\n\n\\- Clostridium difficile CLDT 69219\n\n\\- cryptococcal antigen CRYN 69219\n\n\\- group B streptococcus STB 69219\n\n\\- Haemophilus influenzae HI 69219\n\n\\- herpes simplex virus HSV 69223\n\n\\- Neisseria gonorrhoeae GON 69219\n\n\\- Neisseria meningitidis NMG 69219\n\n\\- respiratory syncytial virus RSVN 69219\n\n\\- Streptococcus pneumoniae SPN 66219\n\n\\- Varicella zoster VCZN 69219\n\nMicropolyspora faeni MIC 69229\n\nMicroscopic examination of:\n\n\\- faeces for parasites OCP 69203\n\n\\- material other than blood M 69201\n\nMicroscopy & culture of:\n\n\\- material from nose, throat, eye or ear MCS1 69205\n\n\\- material from skin, superficial sites,\n\nurethra, vagina, cervix or rectum MCS2 69207\n\n\\- post-op wounds, aspirations of body\n\ncavities, synovial fluid, CSF\n\nSCHEDULE—continued\n\n& op/biopsy specimens MCS3 69209\n\n\\- specimens of sputum MCS2 69207\n\n\\- specimens of sputum, urine\n\nor other body fluids for mycobacteria AFB 69213\n\nMucin-like carcinoma associated antigen MCA 66261\n\nMycobacteria microscopy & culture of sputum AFB 69213\n\nN-acetyl procainamide NAPC 66235\n\nNeisseria meningitidis antigens NMG 69219\n\nNeural tube defects/Down syndrome NTDD 66321\n\nNeuron-specific enolase NSEN 66261\n\nNeutrophil functions NFT 71135\n\nNickel NI 66277\n\nNitrazepam NITR 66235\n\nNordothiepin NDIP 66235\n\nNorfluoxetine NFLE 66235\n\nNortriptyline NORT 66235\n\nOestradiol E2 66301\n\nOestriol E3 66301\n\n\\- for Down syndrome testing NTDD 66321\n\nOestrone E1 66301\n\nOligoclonal proteins OGP 71065\n\nOsmolality, serum or urine OSML 66223\n\nOxalate OXAL 66273\n\nOxazepam OXAZ 66235\n\nPAA (phenyl acetic acid) PAA 66281\n\nPalmitic acid in amniotic fluid PALM 66243\n\nParacetamol PARA 66235\n\nParaprotein investigation\n\n\\- by electrophoresis EPPI 66245\n\n\\- by immunoelectrophoresis or immunofixation PPRO 71061\n\n\\- on concurrently collected serum or urine PPSU 71063\n\nParaquat PARQ 66235\n\nParathyroid hormone (PTH) PTH 66301\n\nPartial thromboplastin time PTT 65029\n\nPassovy factor PF 65045\n\nPatient episode initiation fees PEI 73901-15\n\nPentobarbitone PENT 66235\n\nPentagastrin PSTR 66297\n\nPerhexiline PHEX 66235\n\npH measurement of body fluids other than urine PH 66213\n\nPhenobarbitone PHBA 66235\n\nPhensuximide PHEN 66235\n\nPhenylacetic acid PAA 66281\n\nPhenytoin PHEY 66235\n\nSCHEDULE—continued\n\nPhosphate PHOS 66201\n\nPhosphatidylglycerol PTGL 66243\n\nPlasminogen PLAS 65037\n\nPlatelet\n\n\\- aggregation PLTG 65041\n\n\\- count PLTC 65001\n\nPorphyrins (quantitative test, 1 or more\n\nfractions) PR 66281\n\nPotassium K 66201\n\nPrealbumin PALB 66259\n\nPrednisolone PRED 66235\n\nPregnancy serology\n\n\\- 1 estimation MSP1 69253\n\n\\- 2 estimations MSP2 69255\n\n\\- 3 estimations MSP3 69257\n\n\\- for Down syndrome testing NTDD 66321\n\nPrimidone PRIM 66235\n\nProcainamide PCAM 66235\n\nProgesterone PROG 66301\n\nProlactin PROL 66301\n\nProminal PROM 66235\n\nPropranolol PPNO 66235\n\nProstate specific antigen PSA 66259\n\nProstatic acid phosphatase ACP 66259\n\nProtein\n\n\\- C PROC 65037\n\n\\- S PROS 65037\n\n\\- quantitative estim. of specific protein\n\n\\- alpha fetoprotein AFP 66259\n\n\\- for Down syndrome testing NTDD 66321\n\n\\- alpha-l-antitrypsin AAT 66255\n\n\\- alpha-2-macroglobulin AMAC 66255\n\n\\- beta-2-microglobulin BMIC 66259\n\n\\- C-l esterase inhibitor CEI 66257\n\n\\- caeruloplasmin CPLS 66259\n\n\\- classes by electrophoresis EPPI 66245\n\n\\- ferritin (see also Iron studies) FERR 66259\n\n\\- haptoglobins HGLB 66259\n\n\\- microalbumin MALB 66259\n\n\\- transferrin (see also Iron studies) TRAN 66259\n\n\\- total PROT 66201\n\nProthrombin time PT 65029\n\nPyruvate PVTE 66273\n\nQuinalbarb QUIB 66235\n\nSCHEDULE—continued\n\nQuinidine QUIN 66235\n\nQuinine QNN 66235\n\nRAST RAST 71079\n\nRed cell folate & serum B12 & serum folate if required RCF 66267\n\nRed cell porphyrins - qualitative test RCP 65027\n\nRenin REN 66301\n\nRespiratory syncytial virus antigens RSVN 69219\n\nReticulocyte count RETC 65001\n\nRheumatoid factor RF 71105\n\n\\- factor quantitation RFQ 71107\n\nRSV- respiratory syncytial virus RSVN 69219\n\nRubella serology RUB 69229\n\nSalicylate - aspirin SALI 66235\n\nSecretin SSGR 66297\n\nSelenium SE 66277\n\nSemen examination SEE 73523\n\n\\- for spermatozoa (post vasectomy) SES 73521\n\nSerotonin 5HT 66273\n\nSerology - in pregnancy (see Pregnancy serology)\n\nSerum\n\n\\- Bl2 B12 66265\n\n\\- folate (with Bl2) FOL 66265\n\n\\- folate (with Bl2 red cell folate) RCF 66267\n\nSex hormone binding globulin SHBG 66301\n\nSnake venom HISS 66231\n\nSodium NA 66201\n\nSolid tissue or tissues - chemical assays ENZS 66285\n\nSomatomedin SOMA 66301\n\nSotalol SALL 66235\n\nSpecific IgG or IgE antibodies RAST 71079\n\nSperm antibodies SAB 73525\n\n\\- penetrating ability SPA 73525\n\nStelazine STEL 66235\n\nStreptococcus pneumoniae antigens SPN 69219\n\nStrontium SR 66277\n\nSulthiame (Ospolot) SUL 66235\n\nSynacthen stimulation test SYNS 66297\n\nSyphilis serology STS 69231\n\nTestosterone TES 66301\n\nThalassaemia studies TS 65011\n\nTheophylline THEO 66235\n\nThiopentone TOPO 66235\n\nThioridazine THIO 66235\n\nThrombin time TT 65029\n\nSCHEDULE—continued\n\nThyroglobulin TGL 66261\n\nThyroid\n\n\\- function tests TFT 66291\n\n\\- stimulating hormone TSH 66301\n\nThyrotrophin releasing hormone test TRH 66293\n\nTotal free fatty acids TFFA 66273\n\nTransferrin (see also Iron studies) TRAN 66259\n\nTriglycerides TRIG 66201\n\nTrimipramine TRIM 66235\n\nTSH (where not requested as part of a thyroid function test) TSH 66301\n\nTumour markers\n\n\\- CA-15.3 antigen CA15 66261\n\n\\- CA-19.9 antigen CA19 66261\n\n\\- CA-125 antigen C125 66261\n\n\\- carcinoembryonic antigen CEA 66261\n\n\\- mammary serum antigen MSA 66261\n\n\\- mucin-like carcinoma associated antigen MCA 66261\n\n\\- neuron specific enolase NSEN 66261\n\n\\- prostate specific antigen PSA 66259\n\n\\- prostatic acid phosphatase-1 or more fractions ACP 66259\n\n\\- thyroglobulin TGL 66261\n\nTryptic activity in faeces TAF 66323\n\nUrate URAT 66201\n\nUrea U 66201\n\nUrine\n\n\\- bilirubin UBIL 66213\n\n\\- cystine (cysteine) UCYS 66213\n\n\\- haemoglobin UHB 66213\n\n\\- melanin (melanogen) UML 66213\n\n\\- microscopy, culture, identification & sensitivity UMCS 69217\n\n\\- myoglobin UMY 66213\n\n\\- porphobilinogen UPG 66213\n\n\\- porphyrins (qualitative test) UPR 66213\n\n\\- steroid fraction or fractions USF 66301\n\n\\- urobilinogen UUB 66213\n\nValproate (Epilim) VALP 66235\n\nVancomycin VAN 66235\n\nVaricella zoster antigens VCZN 69219\n\nVasoactive intestinal peptide VIP 66301\n\nVasopressin ADH 66301\n\nViscosity of blood or plasma VISC 65001\n\nVitamins\n\n\\- B12 RCF 66267\n\n\\- D VITD 66271\n\nSCHEDULE—continued\n\n\\- folate RCF 66267\n\n\\- quantitative estimation of A, B1, B2, B3, B6, C or E VIT 66269\n\nVMA (see HMMA)\n\nVon Willebrands factor VWF 65045\n\nVon Willebrands factor antigen VWA 65045\n\nWarfarin WFR 66235\n\nXylose XYL 66273\n\nZinc ZN 66273\n\n\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n\nNOTE\n\n> Note: 1. Notified in the Commonwealth of Australia Gazette on 27 October 1992.","sortOrder":0}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-realtime","completionTokens":2917},"content_quality":"ok","complexity_score":8,"scope_assessment":{"changed":false,"description":"The legislation remains focused on its original purpose of prescribing the pathology services table and fees for the 1992-1993 period. While lengthy and detailed, it does not expand beyond the administrative function of setting out Medicare benefits for laboratory testing under the Health Insurance Act 1973."},"complexity_factors":["Detailed schedule with over 200 individually numbered service items (65001-73921) across 11 distinct clinical groups","Extensive cross-referencing between items (e.g., 'including any services specified in item 65001')","Nested conditional logic in billing rules (Rule 3 exemptions under Rule 3a with multiple sub-conditions)","Multiple defined terms with statutory meanings ('patient episode', 'recognised pathologist', 'approved pathology authority')","Complex bundling rules determining when multiple tests count as one service vs separate billable events","Dual fee structures: one for the test itself, another for specimen collection (Patient Episode Initiation items)","Specific exclusions for hospital inpatients, prescribed laboratories, and self-collected specimens","Detailed abbreviations section mapping over 150 clinical terms to item numbers"],"plain_english_summary":"The instrument is the Medicare benefits schedule for pathology services for 1992–93, specifying which laboratory and diagnostic tests the government will subsidise and the fees payable to approved pathology practitioners. It covers hundreds of tests across haematology, chemistry, microbiology, immunology, histo/cytopathology, genetics and pregnancy/fertility.\n\nIt also sets billing rules—specific over general, bundling into patient episodes, inpatient/urgent/test-transfer exceptions—and separate specimen-collection fees by location."},"flash_summary":{"complexity_score":8,"scope_assessment":{"changed":true,"description":"Yes. The instrument expressly repeals earlier statutory rules (Regulation 3) and replaces the previously prescribed pathology services table by prescribing a new Schedule for 1992–93 (Regulation 4 and Schedule). It not only updates itemised fees but also clarifies and adds interpretative rules (e.g. Rules 3, 3a, 5, 5a and Rule 11) that affect how services are bundled, exempted and referred, thereby altering the practical billing scope compared with the repealed instruments."},"complexity_factors":["Extensive, itemised fee schedule spanning hundreds of distinct pathology items (Schedule items 65001–73921) increases operational and compliance complexity.","Multiple bundling and patient‑episode rules that determine when multiple tests count as a single billable episode (Schedule Rules 1, 3, 4, 5, 6–10).","Specific exemptions and conditional rules (Rule 3a) requiring endorsements ('Rule 3 Exemption') and staff/recognised pathologist involvement (Rule 3a(1)(e)) add administrative steps and eligibility checks.","Cross‑references to the Health Insurance Act (e.g. subsection 4a(2), subsection 16a(1) and (6), subsection 61(3)) and to other tables (general medical services, diagnostic imaging) create interpretative dependencies (Schedule rule 1(3); Regulation 4).","Temporal caps and lookback windows scattered through the Schedule (14 days, 24 hours, 28 days, 6 months, 12 months) require practitioners to track episode timing precisely (Rules 3, 5, 6–8, various item limits).","Special inter‑laboratory provisions for designated services and referrals (Rule 5a; items 73901–73917 and 73921) change who may claim which items and when.","Eligibility constraints for specific items (e.g. item‑specific patient groups, hospital/recognised laboratory exceptions at Rule 11(2)–(4)) increase billing conditionality.","Large set of abbreviations and groupings (ABBREVIATIONS section) and tiered item groupings (P1–P11) make correct code selection non‑trivial for billing staff."],"plain_english_summary":"These Regulations prescribe the 1992–93 pathology services table under the Health Insurance Act 1973, listing individual pathology items, the fee for each, and detailed billing rules about when tests are bundled, repeated, referred or exempted. They affect approved pathology practitioners, approved pathology authorities, recognised pathologists, treating practitioners and patients by determining which laboratory services attract a Health Insurance Act benefit and how those services must be billed (patient‑episode aggregation, exemptions, referral and initiation fees)."}},"importantCases":[],"_links":{"self":"/api/acts/health-insurance-1992-1993-pathology-services-table-regulations","history":"/api/acts/health-insurance-1992-1993-pathology-services-table-regulations/history","analysis":"/api/acts/health-insurance-1992-1993-pathology-services-table-regulations/analysis","conflicts":"/api/acts/health-insurance-1992-1993-pathology-services-table-regulations/conflicts","importantCases":"/api/acts/health-insurance-1992-1993-pathology-services-table-regulations/important-cases","documents":"/api/acts/health-insurance-1992-1993-pathology-services-table-regulations/documents"}}